Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.

Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S, Urata M, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Kai Y, Isobe T, Kohrogi H, Saito H.

Pharmacogenomics. 2012 Apr;13(5):615-24. doi: 10.2217/pgs.11.176.

PMID:
22462752
2.

Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.

Motoshima K, Nakamura Y, Sano K, Ikegami Y, Ikeda T, Mizoguchi K, Takemoto S, Fukuda M, Nagashima S, Iida T, Tsukamoto K, Kohno S.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1299-1304.

PMID:
24121455
3.

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.

Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.

Cancer Chemother Pharmacol. 2012 May;69(5):1241-6. doi: 10.1007/s00280-012-1831-0. Epub 2012 Jan 26.

PMID:
22278730
4.

Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).

Yamada K, Takayama K, Kawakami S, Saruwatari K, Morinaga R, Harada T, Aragane N, Nagata S, Kishimoto J, Nakanishi Y, Ichinose Y.

Jpn J Clin Oncol. 2013 Jun;43(6):629-35. doi: 10.1093/jjco/hyt056. Epub 2013 Apr 18.

PMID:
23599349
5.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.

PMID:
21684626
6.

Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.

Tamura M, Kondo M, Horio M, Ando M, Saito H, Yamamoto M, Horio Y, Hasegawa Y.

Nagoya J Med Sci. 2012 Feb;74(1-2):133-40.

7.

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ.

J Clin Oncol. 2008 Mar 1;26(7):1119-27. doi: 10.1200/JCO.2007.13.1128.

PMID:
18309947
8.

Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.

White-Koning M, Civade E, Geoerger B, Thomas F, Le Deley MC, Hennebelle I, Delord JP, Chatelut E, Vassal G.

Clin Cancer Res. 2011 Jul 15;17(14):4862-71. doi: 10.1158/1078-0432.CCR-10-3278. Epub 2011 Jun 8.

9.

Screening for epidermal growth factor receptor mutations in lung cancer.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group.

N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.

10.

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA.

J Clin Oncol. 2008 May 10;26(14):2350-7. doi: 10.1200/JCO.2007.15.2280.

PMID:
18467727
11.

[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].

Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.

Zhongguo Fei Ai Za Zhi. 2012 May;15(5):299-304. doi: 10.3779/j.issn.1009-3419.2012.05.09. Chinese.

12.

[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].

Tang CH, Liu XQ, Gao HJ, Li JJ, Guo WF, Li XY, Wang WX, Liu B, Qu LL, Wang WW.

Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):143-7. Chinese.

PMID:
20403247
13.

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K.

Lung Cancer. 2005 Dec;50(3):393-9. Epub 2005 Sep 8.

PMID:
16153743
14.

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA.

N Engl J Med. 2005 Jul 14;353(2):133-44. Erratum in: N Engl J Med. 2006 Oct 19;355(16):1746.

15.

Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.

Matsuura S, Inui N, Ozawa Y, Nakamura Y, Toyoshima M, Yasuda K, Yamada T, Shirai T, Suganuma H, Yokomura K, Suda T, Chida K.

Jpn J Clin Oncol. 2011 Aug;41(8):959-63. doi: 10.1093/jjco/hyr079. Epub 2011 Jun 28.

PMID:
21715361
16.

Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.

Hata A, Katakami N, Kunimasa K, Yoshioka H, Fujita S, Kaji R, Tachikawa R, Tomii K, Imai Y, Iwasaku M, Ishida T.

Jpn J Clin Oncol. 2011 Dec;41(12):1366-72. doi: 10.1093/jjco/hyr159. Epub 2011 Nov 3.

PMID:
22058419
17.

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.

Kobayashi H, Sato K, Niioka T, Miura H, Ito H, Miura M.

Clin Lung Cancer. 2015 Jul;16(4):274-81. doi: 10.1016/j.cllc.2014.12.004. Epub 2014 Dec 11.

PMID:
25554506
18.

Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.

Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, Hirata K.

Osaka City Med J. 2012 Jun;58(1):25-34.

PMID:
23094511
19.

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.

Fujiwara Y, Hamada A, Mizugaki H, Aikawa H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H, Yamamoto N, Ohe Y.

Cancer Sci. 2016 Aug;107(8):1117-23. doi: 10.1111/cas.12983. Epub 2016 Jul 21.

20.

Erlotinib in previously treated non-small-cell lung cancer.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group.

N Engl J Med. 2005 Jul 14;353(2):123-32.

Supplemental Content

Support Center